A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes

Published:2016-02-02 Issue:3 Volume:15 Page:393-402
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Neeland Ian J.,Salahuddin Usman,McGuire Darren K.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

UT Southwestern Medical Center

Publisher

Informa Healthcare

Subject

Pharmacology (medical),General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14740338.2016.1135900

Reference41 articles.

1. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

2. Phlorizin: a review

3. Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

4. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

5. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin combined with short-term intensive insulin therapy improves glycemic variability and 1,5-anhydroglucitol in patients with type 2 diabetes: a randomized clinical trial;International Journal of Diabetes in Developing Countries;2023-10-31

2. Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement;Current Molecular Pharmacology;2023-08

3. New Insights into the Use of Empagliflozin—A Comprehensive Review;Biomedicines;2022-12-19

4. Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial;BMC Endocrine Disorders;2022-11-28

5. Empagliflozin induces apoptotic-signaling pathway in embryonic vasculature: In vivo and in silico approaches via chick’s yolk sac membrane model;Frontiers in Pharmacology;2022-09-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3